Global

Life insurers are moving from pricing metabolic risk to trying to reduce it

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

The Pandemic Deal Has A Hole.

As GLP-1 use scales, dermatology is becoming part of obesity care

When a Cardiology Trial ‘Wins’, What Actually Improved?

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Plague Never Left.

Roche’s Nearly $2B Atavistik Bet Goes After Cardiometabolic Targets Other Drugs Struggle to Reach

FDA Told a Promising ADC: Not Yet.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
